I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| natural killer cell | 14 studies | 20% ± 4% | |
| CD16-positive, CD56-dim natural killer cell, human | 13 studies | 21% ± 6% | |
| CD8-positive, alpha-beta T cell | 13 studies | 21% ± 4% | |
| effector memory CD8-positive, alpha-beta T cell | 9 studies | 21% ± 5% | |
| mature NK T cell | 9 studies | 19% ± 2% | |
| gamma-delta T cell | 8 studies | 19% ± 4% | |
| CD8-positive, alpha-beta memory T cell | 7 studies | 20% ± 4% | |
| T cell | 5 studies | 23% ± 8% | |
| CD16-negative, CD56-bright natural killer cell, human | 5 studies | 21% ± 6% | |
| naive thymus-derived CD8-positive, alpha-beta T cell | 5 studies | 20% ± 4% | |
| effector memory CD8-positive, alpha-beta T cell, terminally differentiated | 5 studies | 20% ± 4% | |
| regulatory T cell | 4 studies | 19% ± 1% | |
| lymphocyte | 4 studies | 26% ± 8% | |
| mucosal invariant T cell | 3 studies | 19% ± 2% | |
| plasma cell | 3 studies | 23% ± 6% |
